Clinical Trial Update: Study to Identify and Describe Predictive Factors for Thromboembolic Events in Patients With High-risk Polycythemia Vera

View source ↗

Summary

This ClinicalTrials.gov study sponsored by Novartis seeks to identify predictive factors for thromboembolic events in high-risk polycythemia vera and is current…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Polycythemia Vera

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Polycythemia Vera | Status: ACTIVE_NOT_RECRUITING